| BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact H Rizos, AM Menzies, GM Pupo, MS Carlino, C Fung, J Hyman, LE Haydu, ... Clinical cancer research 20 (7), 1965-1977, 2014 | 597 | 2014 |
| Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma ES Gray, H Rizos, AL Reid, SC Boyd, MR Pereira, J Lo, V Tembe, ... Oncotarget 6 (39), 42008, 2015 | 368 | 2015 |
| Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma JH Lee, GV Long, S Boyd, S Lo, AM Menzies, V Tembe, A Guminski, ... Annals of Oncology 28 (5), 1130-1136, 2017 | 331 | 2017 |
| Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma M Irvine, A Stewart, B Pedersen, S Boyd, R Kefford, H Rizos Oncogenesis 7 (9), 72, 2018 | 100 | 2018 |
| Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticulum stress A Croft, KH Tay, SC Boyd, ST Guo, CC Jiang, F Lai, HY Tseng, L Jin, ... Journal of Investigative Dermatology 134 (2), 488-497, 2014 | 94 | 2014 |
| Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients MS Carlino, C Fung, H Shahheydari, JR Todd, SC Boyd, M Irvine, ... Clinical Cancer Research 21 (1), 98-105, 2015 | 89 | 2015 |
| Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor TM Becker, SC Boyd, B Mijatov, K Gowrishankar, S Snoyman, GM Pupo, ... Oncogene 33 (9), 1158-1166, 2014 | 77 | 2014 |
| Oncogenic B-RAFV600E signaling induces the T-box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion SC Boyd, B Mijatov, GM Pupo, SL Tran, K Gowrishankar, HM Shaw, ... Journal of Investigative Dermatology 133 (5), 1269-1277, 2013 | 59 | 2013 |
| Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget. 2015; 6: 42008–18 ES Gray, H Rizos, AL Reid, SC Boyd, MR Pereira, J Lo, V Tembe, ... Clin Cancer Res 22, 567-574, 2016 | 33 | 2016 |
| Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing GM Pupo, SC Boyd, C Fung, MS Carlino, AM Menzies, B Pedersen, ... Biomarker Research 5, 1-4, 2017 | 16 | 2017 |
| Oncogenic B-RAFV600E promotes anchorage-independent survival of human melanocytes TM Becker, S Philipsz, LL Scurr, C Fung, S Haferkamp, RF Kefford, ... Journal of investigative dermatology 130 (8), 2144, 2010 | 13 | 2010 |
| Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing M Carlino, RR Kefford, G Long, AM Menzies, B Pedersen, G Pupo, ... BioMed Central, 2017 | | 2017 |
| In depth immune profiling of the response of melanoma to MAPK inhibition SJ Welsh, S Boyd, H McGuire, M Gonzales, AM Menzies, H Kakavand, ... Cancer Research 76 (14_Supplement), 2650-2650, 2016 | | 2016 |
| Circulating tumor DNA as a biomarker in metastatic melanoma patients treated with anti-PD1 antibodies J Lee, S Boyd, V Tembe, A Menzies, G Long, A Guminski, R Kefford, ... Asia-Pacific Journal of Clinical Oncology 12 (Supplement 4), 48-49, 2016 | | 2016 |
| Oncogenic BRAFV600E promotes anchorage-independent survival of human melanocytes S Haferkamp, T Becker, L Scurr, H Rizos, C Fung, S Philipsz, RF Kefford Experimental Dermatology 20 (2), 197-197, 2011 | | 2011 |
